Autoimmune disease affects an estimated 5–8% of the global population, with women disproportionately impacted. The defining characteristic is the same across conditions as different as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis: the immune system mistakes the body's own tissues for foreign invaders and attacks them. Conventional treatment has long centred on immunosuppression — broadly suppressing immune activity to slow the damage. Mesenchymal Stem Cell therapy operates on a different premise: restoring the immune system's regulatory balance rather than disabling it.

Why autoimmune disease is so difficult to treat

The immune system is not a single organ — it's an intricately balanced network of T-cells, B-cells, regulatory cells, cytokines, and signalling pathways. In healthy function, it discriminates precisely between self and non-self, attacking pathogens while sparing the body's own tissues. In autoimmune disease, this discrimination breaks down. Specific T-cell or B-cell populations become inappropriately activated, drive inflammation against host tissue, and recruit further immune attack.

Conventional therapies — corticosteroids, methotrexate, biologic TNF inhibitors, B-cell depleting agents — work by globally dampening immune activity. They reduce damage but at significant cost: increased infection risk, side-effect burden, long-term medication dependence. The goal of newer regenerative approaches is to restore balance rather than impose suppression.

How MSCs interact with the immune system

Mesenchymal Stem Cells possess a remarkable property: they sense the inflammatory environment around them and respond with a coordinated, multi-pathway immunomodulatory effect. This is not generalized suppression — it's targeted recalibration.

Direct cell-to-cell signalling

MSCs express low levels of HLA Class I and Class II molecules, which means they evade rapid immune detection while themselves engaging with T-cells, B-cells, and natural killer cells. Through direct contact and surface-receptor interactions, MSCs can suppress overactive effector T-cells and promote the expansion of regulatory T-cells (Tregs) — the cells responsible for keeping immune responses in check.

Paracrine secretion

MSCs release a sophisticated cocktail of soluble factors:

Macrophage reprogramming

Macrophages exist on a spectrum from inflammatory M1 to regulatory M2 phenotype. MSCs shift the local population toward M2 — supporting tissue repair and reducing the inflammatory environment that drives autoimmune attack.

Flow cytometry analysis examining immune cell populations
Immune profiling — including T-regulatory cell counts and inflammatory cytokine panels — provides objective measures of MSC therapy response.

Conditions with the most clinical evidence

While stem cell therapy is being studied across many autoimmune conditions, the evidence base is strongest in several specific areas:

Rheumatoid Arthritis (RA)

Multiple peer-reviewed studies have shown MSC therapy can reduce disease activity scores (DAS28), inflammatory markers (CRP, ESR), and joint swelling in patients with established RA, particularly those with insufficient response to conventional DMARDs. MSCs may be administered intravenously or directly into affected joints.

Systemic Lupus Erythematosus (SLE)

Lupus is one of the most-studied autoimmune indications for MSC therapy. Clinical research — particularly from groups in China and the US — has documented improvements in serological markers, organ involvement, and disease activity in refractory lupus patients receiving allogeneic MSC infusion.

Multiple Sclerosis (MS)

MSC therapy is being actively investigated for both relapsing-remitting and progressive MS, with research focused on its capacity to reduce neuroinflammation and potentially support neural protection. Outcome measures in clinical research include relapse rate, disability progression (EDSS), and MRI lesion burden.

Inflammatory Bowel Disease (Crohn's, UC)

One of the strongest evidence bases for MSC therapy is in perianal fistulizing Crohn's disease, where local MSC injection has shown durable healing in patients refractory to conventional therapy. Systemic IBD treatment with MSCs is also under active study.

Other conditions

Active investigation continues across psoriasis, Sjögren's syndrome, type 1 diabetes, autoimmune hepatitis, and graft-versus-host disease — with varying levels of evidence.

Important Distinction

MSC therapy for autoimmune disease is not a cure and does not replace conventional medical management in most cases. It is best understood as an adjunctive regenerative protocol that can support disease control, reduce flare frequency, and in some patients, allow lower doses of conventional immunosuppression — always under coordinated medical supervision.

What an autoimmune protocol looks like

An autoimmune-focused MSC programme at a regulated clinic typically involves:

  1. Comprehensive immunology assessment — disease activity scoring, autoantibody panels, inflammatory markers, organ-specific evaluation, current medication review
  2. Coordination with the patient's primary rheumatologist or specialist — MSC therapy works alongside, not in place of, conventional management
  3. Personalized MSC dosing — typically intravenous infusion, with local injection where indicated. Protocols are usually structured as a series of 2–4 sessions across 6–12 weeks
  4. Quarterly bio-marker tracking — including inflammatory markers, autoantibody trends, and disease-specific scoring
  5. Coordinated medication review — over time, where clinically appropriate, conventional medications may be tapered with the rheumatologist's involvement

Realistic outcomes

↓ Activity Reduced disease activity scores in clinical research
↓ Flares Lower flare frequency & severity in many responders
↑ Quality Improved daily function, fatigue, and quality of life

Response varies significantly. Some patients experience meaningful, sustained improvement; others see modest benefit; a minority do not respond. The variables include disease type, disease duration, severity, current medications, MSC quality, and dosing protocol. A reputable clinic will discuss this honest variability during consultation rather than promising guaranteed results.

For autoimmune patients, the question is not whether MSC therapy is a magic answer — it is whether, as part of a coordinated medical strategy, it can shift the trajectory of disease activity in a meaningful way. For many patients, the evidence increasingly suggests it can.

— VELAR Clinical Team

The VELAR autoimmune approach

Autoimmune protocols at VELAR Center are designed in coordination with each patient's existing rheumatology or specialist team. Each programme uses clinical-grade Wharton's jelly–derived MSCs (≥95% identity, >90% post-thaw viability) delivered via a personalized infusion protocol, with comprehensive bio-marker tracking before, during, and after the cycle. Treatment is positioned as adjunctive — supporting, not replacing, the broader medical management of autoimmune disease.